Taking control of cancer – from your mobile phone https://t.co/LrneGrKAAo https://t.co/j5QrXnH1Oi

Taking control of cancer – from your mobile phone https://t.co/LrneGrKAAo https://t.co/j5QrXnH1Oi

from #Cancer-Sfakianakis via simeraentaxei on Inoreader http://twitter.com/ecancer/status/748554360750235650
via IFTTT Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174

Taking control of cancer – from your mobile phone https://t.co/LrneGrKAAo https://t.co/j5QrXnH1Oi

European doctors: Spaces are going fast for our lung cancer event, make sure to book yours https://t.co/vpLlC2PoKe https://t.co/3R782h3iDc

European doctors: Spaces are going fast for our lung cancer event, make sure to book yours https://t.co/vpLlC2PoKe https://t.co/3R782h3iDc

from #Cancer-Sfakianakis via simeraentaxei on Inoreader http://twitter.com/ecancer/status/748547001424486400
via IFTTT Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174

European doctors: Spaces are going fast for our lung cancer event, make sure to book yours https://t.co/vpLlC2PoKe https://t.co/3R782h3iDc

Building a better healthcare future through collaboration and technology https://t.co/s5syICPDG8 https://t.co/VGuVNotuWn

Building a better healthcare future through collaboration and technology https://t.co/s5syICPDG8 https://t.co/VGuVNotuWn

from #Cancer-Sfakianakis via simeraentaxei on Inoreader http://twitter.com/ecancer/status/748539262547656708
via IFTTT Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174

Building a better healthcare future through collaboration and technology https://t.co/s5syICPDG8 https://t.co/VGuVNotuWn

Sickle cell disease related internet activity is three times less frequent than cystic fibrosis related internet activity

from #Cancer-Sfakianakis via simeraentaxei on Inoreader http://ift.tt/297jgHF
via IFTTT Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174

Sickle cell disease related internet activity is three times less frequent than cystic fibrosis related internet activity

A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma

Abstract

Background

Robatumumab (19D12; MK-7454 otherwise known as SCH717454) is a fully human antibody that binds to and inhibits insulin-like growth factor receptor-1 (IGF-1R). This multiinstitutional study (P04720) determined the safety and clinical efficacy of robatumumab in three separate patient groups with resectable osteosarcoma metastases (Group 1), unresectable osteosarcoma metastases (Group 2), and Ewing sarcoma metastases (Group 3).

Procedure

Robatumumab infusions were administered every 2 weeks and were well tolerated with minimal toxicity. Centrally reviewed response data were available for 144 patients.

Results

Low disease burden was important for osteosarcoma response: three of 31 patients had complete response or partial response (PR) by Response Evaluation Criteria in Solid Tumors (RECIST) in resectable patients (Group 1) versus zero of 29 in unresectable patients (Group 2); median overall survival was 20 months in Group 1 versus 8.2 months in Group 2. In centrally reviewed patients with Ewing sarcoma with PET-CT data (N = 84/115), there were six PR, 23 stable disease, and 55 progression of disease by RECIST at 2 months. Patients with Ewing sarcoma had a median overall survival of 6.9 months. However, responding patients with Ewing sarcoma were allowed to continue on treatment after study closure. A minority of patients with metastatic Ewing sarcoma showed clinical responses and have remained healthy after receiving 25–115 doses of robatumumab with remissions of >4 years duration (N = 6).

Conclusions

These findings show that although the IGF-1R remains an attractive treatment target, additional research is needed to identify responders and/or means to achieve durable remissions in order to successfully exploit IGF-1R signal blockade in Ewing sarcoma (clinicaltrials.gov: NCT00617890).

from #Cancer-Sfakianakis via simeraentaxei on Inoreader http://ift.tt/29tETk6
via IFTTT Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174

A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma

The girl who couldn’t stop laughing : a brain tumour diagnosis https://t.co/EqvUzicsQA https://t.co/kg8QIay3t3

The girl who couldn’t stop laughing : a brain tumour diagnosis https://t.co/EqvUzicsQA https://t.co/kg8QIay3t3

from #Cancer-Sfakianakis via simeraentaxei on Inoreader http://twitter.com/ecancer/status/748524139275771904
via IFTTT Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174

The girl who couldn’t stop laughing : a brain tumour diagnosis https://t.co/EqvUzicsQA https://t.co/kg8QIay3t3

Women at risk of ovarian cancer need more guidance from doctors on their choices

Researchers at Cardiff University have found that online information about ovarian cancer can cause as much worry as comfort for women at high risk of developing the disease, in a new study published in ecancer. For women at an increased risk of ovarian…

from #Cancer-Sfakianakis via simeraentaxei on Inoreader http://ift.tt/29aXCTu
via IFTTT Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174

Women at risk of ovarian cancer need more guidance from doctors on their choices